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     Mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome, is a lysosomal storage disease in which heparan sulfate is accumulated in lysosomes, as well as outside of cells, as the primary storage material. This disease is a complex of four conditions caused by dysfunctions of one of genes coding for lysosomal enzymes involved in degradation of heparan sulfate: SGSH (coding for heparan N-sulfatase) – causing MPS IIIA, NAGLU (coding for -N-acetylglucosaminidase) - causing MPS IIIB, HGSNAT (coding for acetyl CoA -glucosaminide acetyltransferase) - causing MPS IIIC), and GNS (coding for N-acetylglucosamine-6-sulfatase) – causing MPS IIID. The primary storage is responsible for some disease symptoms, but other arise as a result of secondary storage, including glycosphingolipids, and subsequent processes, like oxidative stress and neuroinflammation. Central nervous system is predominantly affected in all subtypes of MPS III. Heparan sulfate and its derivatives are the most commonly used biomarkers for diagnosis and prediction procedures. Currently, there is no therapy for Sanfilippo syndrome, however, clinical trials are ongoing for enzyme replacement therapy, gene therapy and substrate reduction therapy (particularly gene expression-targeted isoflavone therapy).








	Mucopolysaccharidosis type III (or MPS III), known also as Sanfilippo disease, is an inherited lysosomal storage disorder (LSD, for basic reviews, see refs. 1-3). As in all other mucopolysaccharidoses, glycosaminoglycan (GAG) storage is the primary cause of the disease. In MPS III, the only primarily accumulated GAG is heparan sulfate (HS). This compound is a polysaccharide, composed of variably sulfated repeating disaccharide unit (Fig. 1). β-D-Glucuronic acid (GlcA) linked to N-acetylglucosamine (​https:​/​​/​en.wikipedia.org​/​wiki​/​N-Acetylglucosamine" \o "N-Acetylglucosamine​) (2-deoxy-2-acetamido-α-D-glucopyranosyl, GlcNAc) form the most common disaccharide unit in HS, making up about 50% of all disaccharide units in this GAG. Other carbohydrates that occur in HS are: α-L-iduronic acid (​https:​/​​/​en.wikipedia.org​/​wiki​/​Iduronic_acid" \o "Iduronic acid​) (IdoA), 2-O-sulfo-α-L-iduronic acid (IdoA(2S)), 2-deoxy-2-sulfamido-α-D-glucopyranosyl (GlcNS), and 2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-O-sulfate (GlcNS(6S)). 
	Sanfilippo disease is, in fact, a common name for four different genetic disorders, caused by dysfunctions of four different genes, each coding for an enzyme involved in degradation of HS. Therefore, four different subtypes of the disease are distinguished, depending on the particular enzymatic deficiency: heparan N-sulfatase (SGSH) in MPS IIIA (OMIM #252900), -N-acetylglucosaminidase (NAGLU) in MPS IIIB (OMIM #252920), acetyl CoA -glucosaminide acetyltransferase (HGSNAT) in MPS IIIC (OMIM #252930), and N-acetylglucosamine-6-sulfatase (GNS) in MPS IIID (OMIM #252940). A scheme for HS degradation, with indication of enzymes acting at particular stages and corresponding MPS III subtypes if activity of one of them is absent or severely decreased, is presented in Fig. 2.





Although the four subtypes of MPS III arise from dysfunction of different genes and enzymes, symptoms of patients suffering from each subtype are similar. Therefore, clinical presentations of Sanfilippo disease is usually described together for A-D subtypes (1-3).
The major symptoms of Sanfilippo disease are cognitive and neurological defects. Among them, developmental delay, cognitive decline, lack of speech or speech delay, sleep disturbances, seizures, hyperactivity, and aggression-like behavior are the most commonly occurring abnormalities. Somatic symptoms also occur in MPS III, however, they are less severe than in other types of mucopolysaccharidoses and appear very heterogenous among patients. Mild facial dysmorphology may include a dolichocephalic skull shape with a short forehead, prominent eyebrows, an everted and thick lower lip, and an upturned upper lip with a protruding philtrum. Hirsutism, a low hair line, and very coarse, stiff hair are often present, and characteristic changes in hair morphology have been documented (4, 5). Some, but not all, patients display hepatomegally, while splenomegaly occurs rarely. On the other hand, frequent ear and respiratory infections are common. Later in the course of the disease, some orthopedic syndromes may occur, like scoliosis, kyphosis, lumbar lordosis, hip dysplasia, and carpal tunnel syndrome.
	MPS III patients appear normal at birth, and the first symptoms are recognized usually at the ages between 2 and 6 years. Their life span is, on average, between 2 and 3 decades, though some patients can survive longer (6-9).
	It is possible to distinguish 3 phases of Sanfilippo disease, after several months or a few years of the lack of any specific symptoms (10). The first phase is characterized by slower or halted cognitive development, with speech deterioration or deficiency as the most severe sign. Although physical development is usually still normal at this stage of the disease, some behavioral problems may appear. The second phase emerges as progressive cognitive deterioration, sleeping disturbances (some patients may sleep as little as 2-3 hours per night), hyperactivity and extreme behavioral problems (impulsivity to such extent that patients have little or no regard for their own safety, aggression-like behavior which arises from hyperactivity rather than from the will to hurt other persons or animals, autistic behavior, and excessive anxiety). The third phase starts with motor functions declination which is followed by disappearance of behavioral problems when patients lose locomotion. Then, severe dementia, spasticity and swallowing difficulties appear. Patients die usually between second and third decade of life.  
	Recent years revealed some further interesting details regarding clinical presentation of MPS III patients. Comparison of patients suffering from Sanfilippo disease were compared to those with non-metabolic intellectual disabilities. Fewer behavioral difficulties as children aged, and more severe level of cognitive deficiency were found in the former group (11), indicating differences between the symptoms depending on their cause. Nevertheless, it is important to underline the variability in severity of symptoms occurring in MPS III patients. In some of them, only moderate mental retardation can be observed even at the end of the third decade of life (12). Sometimes the symptoms might be so uncharacteristic that Sanfilippo disease is misdiagnosed as idiopathic developmental delay, attention deficit/hyperactivity disorder (ADHD) or autism (2, 13-17). This concerns usually the first phase of the disease, as in the second and third phase the symptoms become more specific (18). 
	Detailed investigations of certain patients suffering from Sanfilippo disease indicated that some previously overlooked symptoms may be characteristic for this disorder. These include dental findings, like obliterated pulp chambers and root canals (19), osteonecrosis of the femoral head and hip dysplasia (20), precocious puberty in boys (21), and tachypnea (22). It is also important to mention that the use of advanced methods allowed to indicate specific changes in the brain, particularly diffuse hypomyelination with thinning of the corpus callosum, revealed by magnetic resonance imaging (23), to assess the sleep problems more precisely (24), to demonstrate compromised blood-brain-barrier integrity (25), and to find a significantly stunted growth (26) of MPS III patients. 
Specific molecular mechanisms of diseases caused by mutations in a single gene can be understand on the basis on detailed genetic and biochemical studies. An example of such studies is a recent report demonstrating the crystal structure of glycosylated heparan N-sulfatase (also called N-sulfoglucosamine sulfohydrolase or SGSH) at 2 Å resolution (27). This enzyme is deficient in MPS IIIA, and the resolved structure provided insight into effects of pathogenic mutations in the SGSH gene on possible reasons of impaired activity and/or stability of its product.  
	Important information about a genetic disease pathomechanism can be obtained in studies on animal models, if they are available. Recent years did bring several interesting studies on mouse models of different subtypes of Sanfilippo disease. A novel MPS IIIA mouse model has been constructed, and female mutant homozygous mice were found to be hyperactive, to have a longer path length, to display rapid exploratory behavior, to spend less time immobile, and to display a reduced sense of danger than female wild-type animals (28). Intriguingly, no significant differences could be detected between male MPS IIIA and wild-type mice (28), which is in contrast to the lack of considerable differences between symptoms of male and female human MPS IIIA patients. Hyperactivity was also observed in the mouse model of MPS IIIB, however, the importance of choosing appropriate test has also been indicated (29). 
	The mechanism of impaired neuronal communication was studied with the use of adrenal chromaffin cells of MPS III mice (30). In the affected cells, there were increased numbers of large and/or elongated chromaffin granules, resembling immature secretory granules, relative to wild-type cells. The number of exocytotic events was also reduced in MPS IIIA cells when compared to healthy one. These results suggested that the biogenesis and/or the cell surface docking and fusion potential of the vesicles is impaired in MPS IIIA which might contribute significantly to neuropathology (30). 
	Neuropathology was also evident in MPS IIIB mice, in both central and peripheral nervous systems (31). Regarding the latter system, lysosomal storage pathology was found in dorsal root ganglia affecting neurons, satellite cells, and Schwann cells. Moreover, MPS IIIB mice developed progressive impairments in sensory functions, with significantly reduced response to pain stimulation. Therefore, HS storage likely affects both afferent and efferent neural signal transduction (31). In accordance to this, neuroinflammation and neurodegeneration was evident in mucopolysaccharidosis III type C mouse model (32). Interestingly, mitochondrial defects could be found in brain neurons. These cells contained enlarged, structurally abnormal mitochondria and revealed impaired mitochondrial energy metabolism (32).


4.	The primary and secondary storage in mucopolysaccharidosis type III, and the disease markers

Since MPS III is caused by deficiency in activity of one of enzymes involved in HS degradation (Fig. 2), this GAG has been considered as the primary storage material. Indeed, significantly increased levels of HS in urine and plasma is routinely detected in patients suffering from Sanfilippo disease (1-3). This was confirmed experimentally in MPS IIIB mouse model (33) and in MPS III patients (34). 
	To understand the molecular pathomechanism of MPS III, it is necessary to consider not only primary, but also secondary storage products, as well as their biochemical and cellular effects on various processes. In fact, we are now convinced that the mechanisms of mucopolysaccharidoses, including Sanfilippo disease, are much more complex than just accumulation of GAG(s) in lysosomes, dysfunction of these organelles and then dysfunction of cells, as it was presumed when the primary causes of these disorders were recognized. It is well established that in MPS III, secondary storage of gangliosides, ceramides, galatosylceramides and sphingomyelin occurs in central nervous system. Recent work on the MPS IIIA mouse model indicated that the storage (both primary and secondary) occurs in both lysosomal and non-lysomal compartments in the brain (35). The primary and secondary storage leads to characteristic cellular and physiological changes, like neuroinflammation, decreased and mislocalized synaptic vesicle associated membrane protein, VAMP2, and decreased post-synaptic protein, Homer-1 (36). 
Since HS is accumulated both in lysosomes and outside the MPS III cells, the important question appeared whether extra-lysosomal storage can cause specific disturbance in cell physiology. Recent studies indicated that exposure of wild-type neural cells to exogenous soluble HS fragments activated integrin-based focal adhesions, which attach cells to the extracellular matrix (37). Defective cell polarisation and oriented migration in response to focal extracellular stimuli in affected cells were observed (37). Therefore, undegraded HS can not only affect cell functions due to its storage in lysosomes, but also influence cell physiology when present outside the cell. Microglial activation, neurodegeneration, and oxidative stress are other effects of the storage (38). It was demonstrated that HS activates microglial cells through toll-like receptor 4, and triggers neuroinflammation. However, the oxidative stress occurs in the brain of MPS IIIB mice independently from the neuroinflammation (38). 
It is always the question if the findings in studies on mice reflect precisely the disease mechanisms occurring in humans. Therefore, development of other disease models is important to see if the observed effects are general or species-specific. The MPS IIIB emu model has been described recently (39). Importantly, it revealed the symptoms, as well as biochemical and cytological changes very similar to those observed in mice and humans (39). This indicates that the disease mechanisms investigated on animal models of MPS III may be common also for humans.
Another important question is if the level of storage reflects the disease severity. If so, such parameter could be used for prediction of the course of MPS III and to monitor tested therapeutic methods. In the study with MPS III patients, it was demonstrated that plasmid HS and urinary GAG levels were linearly associated with both an increased risk of loss of speech and loss of walking (40). Such a relationship was further confirmed in another study (12), indicating that HS levels in plasma and urine might be an appropriate biochemical marker in MPS III. Although other Sanfilippo disease markers have been proposed, including changes in hair morphology assessed by electron microscopy (5) and disability, behavioral and cognitive tests (41, 42), it appears that HS and its derivatives are optimal and the most useful biomarkers. Levels of this GAG, measured in dried blood spots, was suggested as a useful method for MPS III newborn screening (34). 
To use HS as a biomarker, precise determination of its concentration in plasma and/or urine is necessary. Therefore, various approaches were reported to obtain precise and reproducible results when estimating HS levels in samples from MPS III patients. A liquid chromatography/tandem mass spectrometry method for determination and quantification of predominant disaccharide GAG units has been published recently (43). In fact, various modifications of modern biochemical and biophysical methods, allowed for accurate measurement of the amount of HS and its derivatives in tested samples, have been reported (44-53 ). Such methods can be extremely useful in both diagnostic procedures and in assessment of efficacy of various therapeutic approaches. 
The summary of recommendations for laboratory diagnosis of Sanfilippo disease has been presented recently. Determination of GAG, or more precisely – HS, levels was indicated as the first stage, followed by estimation of the enzyme activity and molecular tests to find mutations (54). Characterization of mutations in the SGSH gene, coding for N-sulfoglucosamine sulfohydrolase (an enzyme which is deficient in MPS IIIA), may be facilitated by a multiparametric computational algorithm for comprehensive assessment of genetic mutations in Sanfilippo syndrome type IIIA (55).

5.	Potential therapeutic options for Sanfilippo disease 

Until now, no specific treatment has been registered for Sanfilippo disease. Nevertheless, there are several potential therapeutic options which are being investigated, and clinical trials for some of them were performed or are ongoing. MPS III is a special kind of mucopolysaccharidosis in which central nervous systems is mainly affected. Therefore, enzyme replacement therapy, which is currently used for treatment of MPS I, MPS II, MPS IVA and MPS VI, is considered problematic, as intravenously administered recombinant enzyme cannot cross the blood-brain-barrier efficiently (3). Below, the most promising and/or probable potential therapies for MPS III are discussed briefly.

5.1.	Enzyme replacement therapy
Enzyme replacement therapy (ERT) is based on delivery of an active, recombinant enzyme, which is lacking or deficient in patient’s cells, into the body. The most common method for such delivery is intravenous injection. Although it works for MPS I, MPS II, MPS IVA and MPS VI, Sanfilippo disease is difficult to treat in this way, as somatic symptoms in this disorder are relatively mild, and the enzyme is not able to cross the blood-brain-barrier effectively (3). Nevertheless, attempts to use modified ERTs for MPS III are still ongoing.
One approach to delivery of the enzyme to the central nervous system is intrathecal, rather than intravenous, injection. Such a procedure was confirmed to be safe, when used for 6 months for recombinant human heparan N-sulfatase administration, in studies on cynomolgus monkeys (56). Then, the outcomes of repeated intrathecal injection of the recombinant human enzyme on pathological changes in the MPS IIIA dog brain were compared with those in animals  treated via intra-cisternal or ventricular routes (57). It was found that the intra-spinal injection allowed the enzyme to penetrate into the brain. Moreover, a significant reduction in the primary substrate accumulation, as well as the secondary pathology, was observed in the MPS IIIA dog brain (57). The effect of the site of injection on the treatment efficacy was also studied on the mouse model of MPS IIIA. Ventricular and cisternal injection resulted in the enzyme delivery to brain and spinal cord regions. On the other hand, lumbar infusion allowed for a more restricted enzyme delivery (58). The problem is that while the ventricular route was the most effective, it is also the most invasive of the three methods studied. Experiments with the mouse model of MPS IIIA indicated that effectiveness of intra-cisternal cerebrospinal fluid enzyme replacement therapy strongly depends on the time of treatment initiation, with far the best results obtained when early intervention was performed (59). Currently, a clinical trial (extension of phase I/II), devoted to evaluation of administration of recombinant human heparan N-sulfatase (sulfamidase) in patients with Sanfilippo syndrome type A (MPS IIIA) is being conducted by the Shire company (clinical trial no. NCT01299727 (​http:​/​​/​clinicaltrials.gov​/​show​/​NCT01299727" \o "Current version of study NCT01299727 on ClinicalTrials.gov​) or HGT-SAN-055; reference as on June 27, 2015: https://clinicaltrials.gov/ct2/show/NCT01299727?term=sanfilippo&rank=1). 
Another possibility to deliver the enzyme to brain is construction of a fusion protein, composed of the enzyme and a factor which is actively transported through the blood-brain-barrier. A chimeric heparan N-sulfatase, obtained as a fusion of this enzyme with the signal peptide from iduronate-2-sulphatase and the blood-brain barrier-binding domain from the apolipoprotein B (ApoB-BD), has been constructed. The AAV2/8 viral vector carrying the gene coding for the fusion protein was injected to adult MPS IIIA mice. Efficient blood-brain-barrier transcytosis and restoration of heparan N-sulfatase activity in the brain of treated mice were demonstrated. Moreover, this treatment resulted in an improvement of brain pathology and recovery of a normal behavior of the animals (60). Different strategy was used for more efficient transfer of α-N-acetylglucosaminidase, an enzyme deficient in MPS IIIB to cells. The recombinant enzyme was fused to the receptor-binding motif of insulin-like growth factor 2 to enhance its ability to enter cells using the cation-independent mannose 6-phosphate receptor. The fusion protein revealed an enhanced cellular uptake by MPS IIIB fibroblasts while maintaining the enzymatic activity (61). In subsequent studies, to bypass the blood-brain barrier, the fusion protein, in artificial cerebrospinal fluid, was administered intracerebroventricularly to the brain of MPS IIIB mice. Marked uptake of the administered enzyme was observed in many parts of the brain. Heparan sulfate was reduced to control level, and secondary storage of various compounds was decreased significantly (62).

5.2.	Gene therapy
Since all types of Sanfilippo syndrome - like other mucopolysaccharidoses, and more generally, all lysosomal storage diseases – are monogenic disorders, gene therapy appears to be a very attractive therapeutic option. Nevertheless, although very promising results were obtained in studies on cellular and animal models, this approach is still experimental, though now, first results of clinical trials with MPS III patients are available. An excellent overview on the current stage of gene therapy for LSDs has been published recently (63), thus, in this article we will focus only on recent studies devoted to this kind of treatment of Sanfilippo disease. 
The proof of concept of gene therapy for Sanfilippo syndrome type A was demonstrated in studies on MPS IIIA mice. After the systemic administration of an adeno-associated virus 9 vector bearing the sulfamidase gene, SGSH, under the control of a ubiquitous promoter, it was possible to obtain its expression in brain and in peripheral organs. A decrease in GAG storage in the brain and normalization of GAG levels in peripheral organs was observed. Moreover, the resolution of neuroinflammation and prolongation of survival of treated mice were evident (64). Similar studies were performed with MPS IIIB mice. The animals were treated with intracranial AAV2/5-based vector bearing the NAGLU gene, intravenous lentiviral vector bearing NAGLU or the combination of both. All treatments resulted in significant improvements in motor function and hearing, as well as in a significantly increased median life span (65). Other results suggested that targeting both the systemic and central nervous system disease of MPS IIIB early in life appears to be the most efficacious approach (65). The next step of research on MPS IIIB gene therapy, was administration of the rAAV9-CMV vector bearing the human NAGLU gene (rAAV9- CMV-hNAGLU) to cynomolgus monkeys. Those studies demonstrated an effective and safe profile for systemic rAAV9-CMV-hNAGLU vector delivery in nonhuman primates (66).
The first clinical trial (phase I/II) of a gene therapy for Sanfilippo disease was performed with of an adeno-associated viral vector bearing the SGSH gene (67). Four MPS IIIA children received intracerebral injections. The vector was delivered bilaterally to the white matter anterior, medial, and posterior to the basal ganglia. Safety data indicated good tolerance, absence of adverse events related to the injected product, no increase in the number of infectious events, and no biological sign of toxicity related to immunosuppressive drugs. The clinical improvement of patients was, however, moderate (67). Next clinical trials with gene therapy for Sanfilippo disease have been announced (https://www.rareconnect.org/en/community/sanfilippo-syndrome/article/current-sanfilippo-research-programs-in-the-clinical-stage; June 27, 2015).




Difficulties in delivery of a therapeutic enzyme to the brain have stimulated studies on alternative therapies for Sanfilippo disease. One of them is substrate reduction therapy (SRT). The objective of this method is to decrease the efficiency of synthesis of compounds that cannot be degraded in cells of affected organism (69). 
The first successful attempt to impair HS synthesis was based on the use of [9-(2-carboxyphenyl)-6-diethylamino-3-xanthenylidene]-diethylammonium chloride, a compound known also as rhodamine B. Both production and storage of GAGs were decreased in MPS IIIA fibroblasts after their treatment with this compound in vitro (70). When MPS IIIA mice were injected with rhodamine B, reduction in HS levels and behavioral improvement could be observed (71). Trans-generational exposure to low levels of rhodamine B did not adversely affect litter size and liver function in MPS IIIA mice (72). Nevertheless, it is assumed that higher doses might be toxic for humans (69). The mechanism of rhodamine B-mediated inhibition of GAG synthesis arises from reduction of the frequency of synthesis initiation rather than from shortening of the chains as the expression of genes responsible for the initiation and elongation of GAGs was down-regulated in the presence of this compound (73).
The antisense RNA-mediated technologies allow to decrease the amount of chosen mRNA levels, and thus to impair expression of particular genes. Therefore, the idea was presented to reduce efficiency of GAG synthesis due to down-regulation of genes coding for enzymes involved in the biosynthetic pathway. Indeed, by the use of siRNA or shRNA it was possible to significantly decrease the levels of GAGs in MPS III cells (74, 75). However, the general problems with stability and delivery of RNA molecules to patient’s tissues makes this method still at the stage of pre-clinical experiments.
	There is another possibility to lower the level of GAG synthesis. A specific isoflavone called genistein or 5, 7-dihydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one, has been demonstrated to inhibit GAG synthesis in MPS IIIA and MPS IIIB fibroblasts in vitro (76). Since this inhibition appeared to be due to impairment of the epidermal growth factor receptor activity, and further down-regulation of the signal transduction, which normally leads to stimulation of expression of genes coding for enzymes involved in GAG synthesis, this kind of potential substrate reduction therapy has been called ‘gene expression-targeted isoflavone therapy’ or GET IT (77). This kind of therapy appeared particularly attractive for MPS III, as genistein can cross the blood-brain-barrier with efficiency of several percent. However, apart from positive results of early in vitro experiments and studies and animal models, many controversies appeared regarding GET IT. They were reviewed recently (78), therefore, here we will discuss them only briefly and present the most recent results. 
The controversies started from the in vitro stage of the studies. Although early results indicating the inhibition of GAG synthesis in human MPS fibroblasts by genistein (76, 77, 79) were confirmed in other laboratories (80, 81), recently published report demonstrated opposite results (82). Intriguingly, very recent paper showed again a negative effects of genistein on efficiency of GAG synthesis in cell cultures (83). Moreover, microarray analyses, followed by quantitative RT-PCR, identified particular genes coding for enzymes necessary for GAG synthesis which were inhibited by genistein, while most of genes for GAG lysosomal hydrolases were stimulated by this isoflavone (84). This stimulation was apparently due to positive regulation of the transcription factor EB (TFEB), a master regulator for lysosomal biogenesis and function. Again intriguingly, results for some genes were opposite from those published by another group (83 vs. 84). 
Results of experiments with genistein-treated MPS mice provided another controversy. Despite the very promising reports demonstrating significant reduction of GAG storage in peripheral tissues and brain (85-87), and correction of behavior in MPS IIIB mice (87), recent studies have shown unchanged GAG levels in MPS mice receiving genistein (88). Moreover, some adverse effects were signaled, like decreased body length and femur length, as well as a scrotal hernia and/or scrotal hydrocele in males (88). To make the situation even more complicated, we would like to admit that using the same mouse MPS model, we found a significant decrease in GAG levels in tissues of genistein-treated animals, while we did not observe any adverse effects, including those mentioned above (M. Malinowska et al., manuscript in preparation).     
	Definitely, there must be some factors and/or experimental conditions which are not fully controlled and which differ between experiments. Most probably they influence the results obtained by various research groups. Since genistein acts by binding to EGFR and other membrane receptors, one might speculate that differences in the composition of sera used for in vitro cell cultures might result in changes of cellular responses to genistein. In fact, addition of an excess of EGF to the culture medium significantly modified the effects of genistein on GAG storage in MPS cells (77). Furthermore, different abundance of the membrane receptors on the surfaces of cells in the mouse organism, caused by either differences in genetic backgrounds or local external conditions in animal facilities, might have effects similar to those described above.
	Despite the differences in results of in vitro experiments and studies on animal models, preliminary clinical studies were performed. In the investigations published to date, low doses of genistein (5-15 mg/kg/day, in contrast to 160 mg/kg/day used in experiments with mice), included in the soy isoflavone extracts, were employed. Different results of these studies increased the controversy about the efficacy of GET IT. In some studies, improvement of GAG storage and some clinical parameters (e.g. cognitive abilities, behavior, sleeping, infections) have been reported (89-92), while other researchers did not observe positive effects (93). All these studies were open-label trials which further complicated the interpretation of the results. In the only randomized, crossover, placebo-controlled trial with a genistein-rich soy isoflavone extract (10 mg/kg/day of genistein), followed by an open-label extension study, published to date, a statistically significant decrease in plasma and urinary GAG levels in genistein-treated patients was found, while no clinical changes were observed (94). 
	Definitely, a clinical trial with high dose of pure genistein is necessary to indicate if this compound can be effective in treatment of MPS III patients. Since genistein was demonstrated to be safe during a long period treatment of children with a high dose, with no serious adverse effects in MPS patients treated with at least 12 months with this compound at 150 mg/kg/day (95), such a trial became possible. In fact, phase III, double blinded, randomised, placebo controlled clinical trial of high dose oral genistein aglycone in patients with Sanfilippo syndrome, has already been started (reference as on June 27, 2015:  http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=16209).

5.4.	Other therapies
Other therapies have also been tested for Sanfilippo disease. N-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol or miglustat, is known as an inhibitor of glycosphingolipid synthesis, and is registered as a drug for treatment of Gaucher disease (96) and Nieman-Pick C disease (97). Since glycosphingolipids are secondary storage materials in MPS III, a clinical trial with the use of miglustat in Sanfilippo disease has been conducted. However, neither improvement nor stabilization in behavior problems in the treated patients occurred (98).
In contrast to some other mucopolysaccharidoses, it was reported that bone marrow or hematopoietic stem cell transplantation fails to prevent neurological deterioration in MPS III patients. This was also true when umbilical cord blood-derived stem cell transplantation was performed before appearance of symptoms in patients suffering from MPS IIIA and MPS IIIB (99). On the other hand, contrary to that, repeated administrations of human umbilical cord blood cells improved disease outcomes in a mouse model MPS IIIB (100).





Mucopolysaccharidosis type III is a complex of four genetic conditions, each caused by mutations in one of genes coding for enzymes involved in degradation of heparan sulfate. Therefore, this glycosaminoglycan is accumulated in cells of patients. Such storage, accompanied with secondary storage of glycosphingolipids and subsequent oxidative stress and neuroinflammation, leads to severe and progressive deterioration of functions of the central nervous system. Heparan sulfate, as the primary storage material, is used as a biomarker of the disease. Although no therapy is currently available for MPS III, ongoing clinical trials with enzyme replacement therapy, gene therapy and substrate reduction therapy provide a hope for patients and their relatives.    
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Figure 1.  β-D-Glucuronic acid linked to N-acetylglucosamine (​https:​/​​/​en.wikipedia.org​/​wiki​/​N-Acetylglucosamine" \o "N-Acetylglucosamine​) (2-deoxy-2-acetamido-α-D-glucopyranosyl, GlcNAc) as the most common disaccharide unit in heparan sulfate.

Figure 2. A scheme for heparan sulfate degradation, with indication of enzymes acting at particular stages and corresponding MPS III subtypes, caused by their dysfunctions. 
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